We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) announced that the FDA has accepted the supplemental Biologics License Application (sBLA) seeking label expansion of multiple myeloma drug, Empliciti (elotuzumab). The sBLA seeks approval of Empliciti in combination with Celgene’s Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (r/rMM) in second- or later-line settings.
The sBLA was granted priority review by the FDA. A decision is expected on Dec 27, 2018.
Empliciti is already approved in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone for the treatment of multiple myeloma in patients who have received one to three prior therapies.
Shares of Bristol-Myers have declined 1.9% year to date versus the industry’s increase of 5.2%
The sBLA included data from phase II study – ELOQUENT-3 – which evaluated the Empliciti combination regimen in patients who have received at least two prior therapies or whose disease has relapsed or is resistant to Revlimid and a proteasome inhibitor.
Data from the study showed that patients treated with Empliciti plus Pomalyst and dexamethasone (EPd) had a 46% reduction in risk of disease progression compared to patients receiving only Pomalyst and dexamethasone (Pd). The progression free survival (“PFS”) in EPd arm was 10.3 months compared with 4.7 months in the Pd arm.
Bristol-Myers commercializes Empliciti in collaboration with AbbVie (ABBV - Free Report) . The drug generated sales of $119 million in the first half of 2018. However, the combination therapy, if approved, can provide an important treatment option for patients with relapsed/refractory multiple myeloma whose disease has progressed after treatment with lenalidomide and a proteasome inhibitor.
Meanwhile, the company’s largest cancer drug, Opdivo, continues to excel and expand in new indications and geographies. In June, Opdivo received approval as the first PD-1 inhibitor in China for the treatment of locally advanced or metastatic non-small cell lung cancer after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations. However, the drug faces stiff competition globally from Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Bristol-Myers Squibb Company (BMY - Free Report) announced that the FDA has accepted the supplemental Biologics License Application (sBLA) seeking label expansion of multiple myeloma drug, Empliciti (elotuzumab). The sBLA seeks approval of Empliciti in combination with Celgene’s Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (r/rMM) in second- or later-line settings.
The sBLA was granted priority review by the FDA. A decision is expected on Dec 27, 2018.
Empliciti is already approved in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone for the treatment of multiple myeloma in patients who have received one to three prior therapies.
Shares of Bristol-Myers have declined 1.9% year to date versus the industry’s increase of 5.2%
The sBLA included data from phase II study – ELOQUENT-3 – which evaluated the Empliciti combination regimen in patients who have received at least two prior therapies or whose disease has relapsed or is resistant to Revlimid and a proteasome inhibitor.
Data from the study showed that patients treated with Empliciti plus Pomalyst and dexamethasone (EPd) had a 46% reduction in risk of disease progression compared to patients receiving only Pomalyst and dexamethasone (Pd). The progression free survival (“PFS”) in EPd arm was 10.3 months compared with 4.7 months in the Pd arm.
Bristol-Myers commercializes Empliciti in collaboration with AbbVie (ABBV - Free Report) . The drug generated sales of $119 million in the first half of 2018. However, the combination therapy, if approved, can provide an important treatment option for patients with relapsed/refractory multiple myeloma whose disease has progressed after treatment with lenalidomide and a proteasome inhibitor.
Meanwhile, the company’s largest cancer drug, Opdivo, continues to excel and expand in new indications and geographies. In June, Opdivo received approval as the first PD-1 inhibitor in China for the treatment of locally advanced or metastatic non-small cell lung cancer after prior platinum-based chemotherapy in adult patients without EGFR or ALK genomic tumor aberrations. However, the drug faces stiff competition globally from Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote
Zacks Rank
Bristol-Myers currently has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>